Analysis of resistance to antimycobacterial drugs among MTBC strains isolated from cattle in Poland as a threat to human health

• Autorzy: Weiner M. , Krajewska M. , Zabost A. , Augustynowicz-Kopec E. , Szulowski K.

Warianty tytułu

PL

Analiza oporności na leki przeciwprątkowe wśród szczepów MTBC izolowanych od bydła w Polsce jako zagrożenie dla zdrowia ludzi

• Języki publikacji: EN

Abstrakty

EN

Background. Tuberculosis is a highly contagious disease affecting humans and animals. It is caused by mycobacteria that are part of the Mycobacterium tuberculosis complex (MTBC). The etiological agent causing bovine tuberculosis is mycobacteria bovis: Mycobacterium bovis and Mycobacterium caprae. According to the World Health Organization bovine tuberculosis is classified as direct zoonosis. Material and methods. The study material consisted of 129 MTBC strains isolated from Polish cattle, which were microbiologically analyzed. The resistance phenotype was tested for first-line anti-tuberculosis drugs used in the treatment of tuberculosis in humans. The drugs included streptomycin, isoniazid, rifampicin, ethambutol, and pyrazinamide. The MTBC strains tested in this study were isolated from cattle tissue post mortem so that the determination of drug resistance could meet only the epidemiological criterion. Results. Polish strains of mycobacteria bovis have not acquired environmental resistance despite the huge dynamics of changes in the phenotype of mycobacterial tuberculosis resistance. Strains classified as M. bovis are characterized by natural resistance to PZA, which is typical of this species. Conclusions. Drug resistance imposes the use of additional drugs. Drugs that are less effective than the basic drugs, drugs causing side effects more frequently and drugs that are much more expensive.

PL

Wprowadzenie. Gruźlica jest wysoce zakaźną chorobą ludzi i zwierząt, którą powodują prątki wchodzące w skład kompleksu Mycobacterium tuberculosis (MTBC). Czynnikiem etiologicznym gruźlicy bydlęcej są prątki bydlęce: Mycobacterium bovis i Mycobacterium caprae. Zgodnie z klasyfikacją Światowej Organizacji Zdrowia, gruźlica typu bydlęcego zaliczana jest do zoonoz bezpośrednich. Materiał i metody. W pracy poddano analizie mikrobiologicznej 129 szczepów MTBC wyizolowanych od bydła w Polsce. Fenotyp oporności zbadano pod kątem leków przeciwprątkowych pierwszej linii stosowanych w leczeniu gruźlicy u ludzi: streptomycyny, izoniazydu, rifampicyny, etambutolu i pyrazynamidu. Szczepy MTBC badane w niniejszej pracy wyizolowano z tkanek bydła pobranych post mortem, tak że oznaczenie lekooporności w tym zadaniu spełniło jedynie kryterium epidemiologiczne. Wyniki. Polskie szczepy prątka bydlęcego nie nabyły oporności środowiskowej. Szczepy sklasyfikowane jako M. bovis cechują się charakterystyczną dla tego gatunku naturalną opornością na PZA. Wnioski. Wystąpienie lekooporności zmusza do stosowania leków dodatkowych, mniej skutecznych niż leki podstawowe i powodujących częściej objawy uboczne, a jednocześnie znacznie droższych.

• Wydawca: -
• Czasopismo: Health Problems of Civilization
• Rocznik: 2020
• Tom: 14
• Numer: 1
• Opis fizyczny: p.24-28,fig.,ref.

Twórcy

autor

Weiner M.

• Pope John Paul II State School of Higher Education in Biala Podlaska, Biala Podlaska, Poland

autor

Krajewska M.

• National Veterinary Research Institute in Pulawy, Pulawy, Poland

autor

Zabost A.

• National Tuberculosis and Lung Diseases Research Institute in Warsaw, Warsaw, Poland

autor

Augustynowicz-Kopec E.

• National Tuberculosis and Lung Diseases Research Institute in Warsaw, Warsaw, Poland

autor

Szulowski K.

• National Veterinary Research Institute in Pulawy, Pulawy, Poland

Bibliografia

• 1. Aranaz A, Cousins D, Mateos A, Domínguez L. Elevation of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to species rank as Mycobacterium caprae comb. nov., sp. nov. Int. J Syst. Evol. Microbiol. 2003; 53(6): 1785-1789. https://doi.org/10.1099/ijs.0.02532-0
• 2. Bailey SS, Crawshaw TR, Smith NH, Palgrave CJ. Mycobacterium bovis infection in domestic pigs in Great Britain. Vet. J. 2013; 198(2): 391-397. https://doi.org/10.1016/j.tvjl.2013.08.035
• 3. Beltrán-Beck B, Ballestros C, Vicente J, de la Fuente J, Gortázar C. Progress in oral vaccination against tuberculosis in its main wildlife reservoir in Iberia, the Eurasian wild boar. Vet. Med. Int. 2012; 2012: 978501. https://doi.org/10.1155/2012/978501
• 4. Campbell TA, Long DB, Bazan LR, Thomsen BV, Robbe-Austerman S, Davey RB, et al. Absence of Mycobacterium bovis in feral swine (Sus scrofa) from the southern Texas border region. J. Wildl. Dis. 2011; 47(4): 974-978. https://doi.org/10.7589/0090-3558-47.4.974
• 5. Corner LA. The role of wild animal populations in the epidemiology of tuberculosis in domestic animals: how to assess the risk. Vet. Microbiol. 2006; 112(2-4): 303-312. https://doi.org/10.1016/j.vetmic.2005.11.015
• 6. Crawshaw T, Daniel R, Clifton-Hadley R, Clark J, Evans H, Rolfe S, et al. TB in goats caused by Mycobacterium bovis. Vet. Rec. 2008; 163: 127. https://doi.org/10.1136/vr.163.4.127
• 7. Gallagher J, Clifton-Hadley RS. Tuberculosis in badgers; a review of the disease and its significance for other animals. Res. Vet. Sci. 2000; 69(3): 203-217. https://doi.org/10.1053/rvsc.2000.0422
• 8. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin. Chest Med. 1989; 10: 341-353.
• 9. Jagielski T, Augustynowicz-Kopeć E, Zwolska Z. [Genotyping of Mycobacterium tuberculosis. An overview of the major research techniques (part I)]. Pol. Merk. Lek. 2010; 29(171): 206-211 (in Polish).
• 10. Karlson AG, Lessel EF. Mycobacterium bovis nom. Nov. Int. J. Syst. Bacteriol. 1970; 20: 273-282. https://doi.org/10.1099/00207713-20-3-273
• 11. Krajewska M, Kozińska M, Zwolska Z, Lipiec M, Augustynowicz-Kopeć E, Szulowski K. Human as a source of tuberculosis for cattle. First evidence of transmission in Poland. Vet. Microbiol. 2012; 159(1-2): 269-271. https://doi.org/10.1016/j.vetmic.2012.04.001
• 12. Krajewska M, Napiórkowska A, Augustynowicz-Kopeć E. [Pyrazinamide resistance among Mycobacterium bovis strains isolated from animals in Poland]. Życie Wet. 2013; 88(7): 575-577 (in Polish).
• 13. Krajewska M, Załuski M. [Tuberculosis in giraffe – attempt to treatment]. Paper presented at: Scientific and Training Conference “Pharmacological and environmental aspects of rational therapy”; 2012 Dec 11-14; Krynica Zdrój, Poland (in Polish).
• 14. Krajewska M. [Characterization of Mycobacterium bovis strains isolated from animals in Poland] [dissertation]. Puławy: PIWet-PIB Puławy; 2015 (in Polish).
• 15. Michałowska-Mitczuk D. [Pharmacotherapy of tuberculosis]. Postępy Farmakoterapii. 2009; 65: 51-58 (in Polish).
• 16. Monies RJ, Cranwell MP, Palmer N, Inwald J, Hewinson RG, Rule B. Bovine tuberculosis in domestic cats. Vet. Rec. 2000; 146: 407-408. https://doi.org/10.1136/vr.146.14.407
• 17. Monreal L, Segura D, Segalés J, Garrido JM, Prades M. Diagnosis of Mycobacterium bovis infection in a mare. Vet. Rec. 2001; 149: 712-714. https://doi.org/10.1136/vr.149.23.712
• 18. Muñoz Mendoza M, Juan LD, Menéndez S, Ocampo A, Mourelo J, Sáez JL, et al. Tuberculosis due to Mycobacterium bovis and Mycobacterium caprae in sheep. Vet. J. 2012; 191(2): 267-269. https://doi.org/10.1016/j.tvjl.2011.05.006
• 19. Napiórkowska A, Zwolska Z, Augustynowicz-Kopeć E. [Resistance to pyrazinamide among Mycobacterium tuberculosis strains isolated from patients from the Mazovian Voivodeship in 2008-2010 years]. Post. N. Med. 2011; 24, 819-823 (in Polish).
• 20. Olesiejuk R, Maciak L, Milanowski J. [The importance of the Bactec radiometric method for the introduction of anti-mycobacterium treatment]. Pneumol. Alergol. Pol. 2002; 70: 5-11 (in Polish).
• 21. Osek J, Wieczorek K. [Prevalence of zoonoses in animals and zoonotic agents in food in Europe in 2013]. Życie Wet. 2015; 90: 210-216 (in Polish).
• 22. Rodriguez-Campos S, Smith NH, Boniotti MB, Aranaz A. Overview and phylogeny of Mycobacterium tuberculosis complex organisms: implication for diagnostics and legislation of bovine tuberculosis. Res. Vet. Sci. 2014; 97: S5-S19. https://doi.org/10.1016/j.rvsc.2014.02.009
• 23. Safinowska A, Walkiewicz R, Nejman-Gryz P, Grubek-Jaworska H. [Two selected commercially based nucleic acid amlification tests for the diagnosis of tuberculosis]. Pneumonol. Alergol. Pol. 2012; 80(1): 6-12 (in Polish).
• 24. Shrikrishana D, de la Rua-Domenech R, Smith NH, Colloff A, Coutts I. Human and canine pulmonary Mycobacterium bovis infections in the same household: re-emergence of an old zoonotic threat?. Thorax. 2009; 64: 89-91. https://doi.org/10.1136/thx.2008.106302
• 25. van der Burgt GM, Crawshaw T, Foster AP, Denny DJ, Schock A. Mycobacterium bovis infection in dogs. Vet. Rec. 2009; 165: 634. https://doi.org/10.1136/vr.165.21.634
• 26. Zientek J, Kozielski J, Augustynowicz-Kopeć E, Kozińska M, Zwolska Z. Transmission of tuberculosis among people living in border areas of Poland, Czech Republic and Slovakia. Paper presented at: II Congress of the Czech Pneumological and Phthiseological Society of CLS JEP; 2014 Sep 18-20; Olmuc, Czech Republic.
• 27. Zwolska Z, Augustynowicz-Kopeć E. [Drug-resistant tuberculosis]. Pol. Merk. Lek. 2011; 30: 362-366 (in Polish).

Identyfikatory

DOI

10.5114/hpc.2020.92423